A novel limited-dose C5 inhibitor add-on as rescue therapy for refractory NMOSD attacks: a practical alternative to conventional multi-dose regimens
Open Access
- 16 May 2026
- journal article
- research article
- Published by Springer Nature in BMC Neurology
- Vol. 26 (1)
Abstract
Neuromyelitis optica spectrum disorder (NMOSD) patients with refractory attacks, despite standard therapy with high-dose intravenous methylprednisolone (IVKeywords
All Related Versions
This publication has 37 references indexed in Scilit:
- Immunotherapies for neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease2026
- The impact of autoimmune comorbidities on the onset attack recovery in adults with AQP4-NMOSD and MOGADJournal of Neurology, 2025
- Decreased NETosis-related regulators in neuromyelitis optica spectrum disorders after plasma exchangeInternational Immunopharmacology, 2024
- Eculizumab as rescue therapy in a context of dramatic NMOSD attack: Report of two casesRevue Neurologique, 2024
- Effects of intravenous pulse methylprednisolone in neuromyelitis optica during the acute phaseAnnals of Clinical and Translational Neurology, 2024
- New Treatment Perspectives for Acute Relapses in Neuromyelitis Optica Spectrum DisorderTransfusion Medicine Reviews, 2022
- Long‐Term Safety and Efficacy of Eculizumab in Aquaporin‐4 IgG‐Positive NMOSDAnnals of Neurology, 2021
- Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental modelsMultiple Sclerosis and Related Disorders, 2019
- Neuromyelitis OpticaRheumatic Disease Clinics of North America, 2017
- Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment coursesAnnals of Neurology, 2015